Tvardi shareholders back directors, pay and auditor
Tvardi Therapeutics, Inc. reported the voting results from its Annual Meeting of Stockholders held on June 9, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tvardi Therapeutics, Inc. reported the voting results from its Annual Meeting of Stockholders held on June 9, 2026. Stockholders elected Imran Alibhai, Ph.D., Cynthia Smith and Sujal Shah as Class II directors to serve until the 2029 annual meeting.
They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and indicated a preference for holding this advisory vote every year. In addition, stockholders ratified the Audit Committee’s selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
8-K Event Classification
Key Figures
Key Terms
Annual Meeting of Stockholders regulatory
non-binding advisory basis regulatory
Broker Non-Votes regulatory
independent registered public accounting firm regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tvardi Therapeutics (TVRD) stockholders decide about board elections at the 2026 annual meeting?
How did Tvardi Therapeutics (TVRD) vote on executive compensation in 2026?
What frequency of say-on-pay votes did Tvardi Therapeutics (TVRD) stockholders prefer?
How did Tvardi Therapeutics (TVRD) respond to the say-on-frequency vote outcome?
Which auditor did Tvardi Therapeutics (TVRD) stockholders ratify for fiscal 2026?
Were there significant broker non-votes at Tvardi Therapeutics’ 2026 annual meeting?
AI-generated analysis. How Rhea-AI works. Not financial advice.